Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

AngioDynamics, Inc. - Common Stock (NQ:ANGO)

12.53 -0.25 (-2.00%)

Streaming Delayed Price Updated: 10:27 AM EDT, Jul 14, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	146,863
Open	13.64
Bid (Size)	12.50 (100)
Ask (Size)	12.54 (100)
Prev. Close	12.78
Today's Range	12.31 - 13.64
52wk Range	8.360 - 13.99
Shares Outstanding	38,444,076
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

AngioDynamics Q4 Earnings Call Highlights ↗

Today 9:03 EDT

AngioDynamics (NASDAQ:ANGO) reported higher fiscal fourth-quarter and full-year revenue, driven by continued growth in its med tech portfolio, while management said the company remains focused on...

Via MarketBeat

Full Transcript: AngioDynamics Q4 2026 Earnings Call ↗

Today 9:02 EDT

AngioDynamics (NASDAQ:ANGO) released fourth-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This content is powered by Benzinga APIs. For...

Via Benzinga

Performance

YTD	-1.2%	-1.2%
1 Month	+4.5%	+4.5%
3 Month	+22.3%	+22.3%
6 Month	+23.0%	+23.0%
1 Year	+30.1%	+30.1%

More News

AngioDynamics (NASDAQ:ANGO) Surges on Strong Quarterly Beat as Med Tech Segment Drives Growth ↗

Today 7:20 EDT

Via Chartmill

AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

Today 6:00 EDT

From AngioDynamics, Inc.

Via Business Wire

AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026

June 30, 2026

From AngioDynamics, Inc.

Via Business Wire

AngioDynamics Inc (NASDAQ:ANGO) Beats Q3 Earnings Estimates and Raises Full-Year Guidance ↗

April 02, 2026

Via Chartmill

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

June 17, 2026

From AngioDynamics, Inc.

Via Business Wire

AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect

May 28, 2026

From AngioDynamics, Inc.

Via Business Wire

AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 27, 2026

From AngioDynamics, Inc.

Via Business Wire

AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

May 13, 2026

From AngioDynamics, Inc.

Via Business Wire

Med-Tech Resilience: AngioDynamics Pivot Pays Off with Double-Digit Growth and Profitability

April 02, 2026

Via MarketMinute

AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability

April 02, 2026

From AngioDynamics, Inc.

Via Business Wire

AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference

March 31, 2026

From AngioDynamics, Inc.

Via Business Wire

AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026

March 19, 2026

From AngioDynamics, Inc.

Via Business Wire

Bastion Bets on Government Spending with $8 Million New Stake in Parsons ↗

February 27, 2026

Via The Motley Fool

AngioDynamics to Present at the Leerink Partners Global Healthcare Conference

February 23, 2026

From AngioDynamics, Inc.

Via Business Wire

AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform

February 19, 2026

From AngioDynamics, Inc.

Via Business Wire

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

February 05, 2026

From AngioDynamics, Inc.

Via Business Wire

AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance

February 03, 2026

From AngioDynamics, Inc.

Via Business Wire

AngioDynamics (ANGO) Q1 2026 Earnings Transcript ↗

January 06, 2026

Via The Motley Fool

AngioDynamics (ANGO) Q3 2025 Earnings Transcript ↗

January 06, 2026

Via The Motley Fool

AngioDynamics (ANGO) Q1 2025 Earnings Transcript ↗

January 06, 2026

Via The Motley Fool

AngioDynamics (ANGO) Q2 2026 Earnings Transcript ↗

January 06, 2026

Via The Motley Fool

Why AngioDynamics Stock Is Sinking Today ↗

January 06, 2026

Via The Motley Fool

Traders are paying attention to the gapping stocks in Tuesday's session. ↗

January 06, 2026

Via Chartmill

Frequently Asked Questions

Is AngioDynamics, Inc. - Common Stock publicly traded?

Yes, AngioDynamics, Inc. - Common Stock is publicly traded.

What exchange does AngioDynamics, Inc. - Common Stock trade on?

AngioDynamics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for AngioDynamics, Inc. - Common Stock?

The ticker symbol for AngioDynamics, Inc. - Common Stock is ANGO on the Nasdaq Stock Market

What is the current price of AngioDynamics, Inc. - Common Stock?

The current price of AngioDynamics, Inc. - Common Stock is 12.53

When was AngioDynamics, Inc. - Common Stock last traded?

The last trade of AngioDynamics, Inc. - Common Stock was at 07/14/26 10:27 AM ET

What is the market capitalization of AngioDynamics, Inc. - Common Stock?

The market capitalization of AngioDynamics, Inc. - Common Stock is 481.51M

How many shares of AngioDynamics, Inc. - Common Stock are outstanding?

AngioDynamics, Inc. - Common Stock has 482M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.